#4 - UnitedHealth Group (NYSE:UNH)
Healthcare stocks will continue to be among the best performers in 2022. And as investors hunt for quality, UnitedHealth Group (NYSE:UNH) should get strong consideration.
UnitedHealth is one of the largest companies in the field of managed care. This is expected to be a strong catalyst as hospitals and medical centers continue to recover from the pandemic closures.
And the company has also entered into an agreement to purchase Change Healthcare for $8 billion. The company recently announced this acquisition will not happen until April instead of February as previously thought. That may put the stock under pressure in the short term, but unless the SEC blocks the acquisition on antitrust concerns, this will be another catalyst for UNH stock.
UNH stock is up 43% in 2021 and is currently at the upper range of the analysts’ forecasts. However, in the last month, the stock has seen its price target boosted by a number of firms, most notably Goldman Sachs (NYSE:GS) that sees strong growth in the managed care business.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
Read More - Current Price
- $512.24
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 15 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $570.05 (11.3% Upside)
